Marksans Pharma Share Price Target 2024-2030 Fundamentals & Quarterly Results

Marksans Pharma Share Price Target 2024, 2025, 2026, 2027, 2028, 2029, 2030 Fundamentals & Quarterly Results – Marksans Pharma leads the way in the pharmaceutical industry as it maintains an approach focused on the customers. With a specialization in over-the-counter drugs as well as prescription medication, Marksans has successfully established itself in tight regulatory markets.Marksans Pharma Share Price Target

Marksans Pharma Overview

Marksans Pharma Limited is an Indian pharmaceutical company. It is involved in the manufacture and sale of research pharmaceutical formulations as its core activity. Across multiple therapeutic areas, it offers products for pain control, coughs and colds, heart disease or central nervous system disorders, metabolism improvement and protecting the gastrointestinal tract, balancing hormones in humans, as well as alleviating allergies.

Company NameMarksans Pharma Ltd
Listed atNSE & BSE
Head Office11th Floor, Grandeur, Opp Gundecha Symphony, Off Veera Desai Road, Andheri West, Mumbai 400053
Board Of Directors
  • Chairman – Mark Saldanha
  • Managing Director – Mark Saldanha
  • Company Secretary – Harshavardhan Panigrahi
  • Non Executive Independent Director  – Seetharama Raju Buddharaju
  • Non Executive Independent Director – Digant Mahesh Parikh
  • Non Executive Independent Director – Abhinna Sundar Mohanty
  • Non Executive Independent Director  – Shailaja Vardhan
  • Whole Time Director – Sandra Saldanha
  • Whole Time Director – Varddhman Vikramaditya Jain
  • Non Independent & Non Executive Director – Sunny Sharma
Official Websitemarksanspharma.com

Also Check Tata Elxsi Share Price Target

Marksans Pharma Business Profile

Marksans Pharma manufactures drug formulations for the pharmaceuticals sector. Its main areas of interest are in OTC and prescribed drugs which are widely used in a broad spectrum of applications including treatments for cancers, infections in the stomach, diabetes, inflammations, heart related issues, pain relievers, among others.

Also Check Union Bank Share Price Target

Product Portfolio

The company has over one thousand five hundred stock-keeping units and more than three hundred products in different formulations, including tablets (plain, enteric coated and film coated), as well as hard & soft gelatin capsules and oral liquids or ointments.

Also Check Himadri Share Price Target

Operation Overview

USA – In June 2015, Co bought Time Cap Labs Inc. This particular WoS is servicing the region. Their product lines are divided across Private Label OTC, Generic Prescription Drugs – with over 50 items on the list thereof. Customers range from Target to Walmart to Walgreens and Kroger among others.

Also Check IFCI Share Price Target

UK and Europe- The region is serviced by two subsidiaries owned by The Co, which are Relonchem and Bells Healthcare. Private label & branded cough liquids in the UK are mainly from Bells Healthcare which is the biggest manufacturer while Relonchem provides a wide selection of own label healthcare pharmaceutical products. This has improved its distribution and penetration into the UK market because the Co has partnered with key retailers in the UK like Tesco, Asda, Morrisons, Coop and Boots.

Also Check Bank of Maharashtra Share Price Target

Australia and New Zealand – Marksans Pharma collaborates with major retailers and pharmacies in Australia such as Woolworths Ltd., Coles Mayer Ltd., Aldis, Metcash and Fauldings as well as through partnership between Teva/ Arrow Pharma for the New Zealand pharmaceutical market.

New Products List

USA – 32 products are in the pipeline, 20 are oral solids, 12 are ointments and creams, 4 are Softgels.
UK – Planned 34 new filings in next 3 yrs. + 16 products awaiting approval.
Australia and New Zealand – 10 products are in the pipeline and expected to be launched
over the next 2 yrs.
ROW – 124 products approved, 120 awaiting
approval & 108 in the pipeline.

Also Check Olectra Greentech Share Price Target

Acquisition & Capex

In April, 2023, Marksans acquired Teva’s manufacturing unit in a bid to expand its current capacities by a total capex of Rs. 200 crs. For FY24, preacquisition of Rs. 160 crs. by the company was already underway, which included Rs 78 crs acquisition expenses Capex FY23 amounted to approximately 53 crores.

Also Check CDSL Share Price Target

New Approval

on October 23, the company received US FDA approval for Esomeprazole Magnesium Delayed-Release Capsules USP, 20 mg (OTC). In speech of AstraZeneca Pharmaceuticals LP, the Nexium 24 HR Delayed Release Capsules are bio equivalent. In Goa the production of the new drug will take place.

Also Check IDFC First Bank Share Price Target

Subsidiaries

1.  Marksans Holdings Ltd (UK) – WOS
2.  Marksans Pharma Inc (US) – WOS
3.  Nova Pharmaceuticals Australasia Pty Ltd. (Australia) – 60% stake
4.  Access Healthcare for Medical Products LLC (UAE) – WOS

Also Check Orient Green Power Share Price Target

Marksans Pharma Fundamentals & Quarterly Results

Market Cap₹ 7,509 Cr.
Current Price₹ 166
High / Low₹ 186 / 70.2
Stock P/E23.7
Book Value₹ 41.4
Dividend Yield0.30 %
ROCE22.2 %
ROE18.6 %
Face Value₹ 1.00
Debt to equity0.06
Debt Capacity0.14
Debt preceding year₹ 111 Cr.
Debt₹ 111 Cr.
Reserves₹ 1,830 Cr.
EPS₹ 7.00
EPS last year₹ 5.88
Pledged percentage0.00 %
FCF Prev Ann₹ 53.0 Cr.
EVEBITDA13.8
Industry PE27.0
PEG Ratio0.46
Piotroski score7.00
Earnings yield6.30 %
Sales growth 5Years15.2 %

Also Check ONGC Share Price Target

Marksans Pharma Quarterly Results

MetricDec 2020Mar 2021Jun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023
Sales358330349361363418434453480486500531586
Expenses267235272301305354361372403376398417453
Operating Profit919577605864738077110102114133
OPM %25%29%22%17%16%15%17%18%16%23%20%21%23%
Other Income-366912151614181110195
Interest2312152322223
Depreciation917792111141314141822
Profit before tax78977560605376787910497114113
Tax %24%18%16%23%20%44%21%23%21%21%27%26%26%
Net Profit59806346483060606283708483
EPS in Rs1.441.941.531.111.180.691.461.511.571.811.521.841.84

CAGR Report

Compounded Sales Growth:

Time PeriodGrowth Rate
10 Years16%
5 Years15%
3 Years18%
TTM18%

Compounded Profit Growth:

Time PeriodGrowth Rate
10 Years19%
5 Years52%
3 Years30%
TTM51%

Stock Price CAGR:

Time PeriodCAGR
10 Years20%
5 Years48%
3 Years30%
1 Year126%

Return on Equity:

Time PeriodROE
10 Years20%
5 Years21%
3 Years22%
Last Year19%

Marksans Pharma Shareholding Pattern

Shareholder TypeSep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024
Promoters48.60%49.00%43.85%43.85%43.85%43.85%43.85%
FIIs4.06%4.23%15.11%14.90%15.07%15.55%15.57%
DIIs0.95%0.96%1.46%3.65%4.02%4.76%5.17%
Public46.38%45.79%39.57%37.60%37.06%35.81%35.40%
No. of Shareholders2,17,7432,13,1231,98,3821,88,4472,07,9372,37,3772,54,699

Marksans Pharma Share Price Target 2024-2030 Forecast

YearTarget
2024228
2025276
2026293
2027334
2028370
2029400
2030450

Marksans Pharma Share Price Target 2025

MonthsTarget Prices
January235
February240
March230
April237
May244
June240
July248
August255
September252
October257
November268
December276

Marksans Pharma Share Price Target 2026

MonthsTarget Prices
January280
February274
March269
April271
May277
June282
July285
August290
September283
October284
November290
December293

Marksans Pharma Share Price Target 2027

MonthsTarget Prices
January301
February293
March287
April294
May300
June306
July319
August311
September320
October325
November329
December334

Marksans Pharma Share Price Target 2028

MonthsTarget Prices
January340
February331
March326
April330
May337
June344
July350
August357
September363
October360
November364
December370

Marksans Pharma Share Price Target 2029

MonthsTarget Prices
January363
February355
March350
April357
May364
June370
July374
August380
September384
October389
November394
December400

Marksans Pharma Share Price Target 2030

MonthsTarget Prices
January415
February402
March393
April396
May405
June414
July420
August429
September423
October430
November440
December450

Official Website –marksanspharma.com

Leave a Comment